Wissing K M, Desalle F, Abramowicz D, Willems F, Leo O, Goldman M, Alegre M L
Département de Néphrologie, Hôpital Erasme, Brussels, Belgium.
Transplantation. 1999 Sep 15;68(5):677-84. doi: 10.1097/00007890-199909150-00014.
Activating anti-CD3 monoclonal antibodies (mAbs), such as OKT3, are potent immunosuppressive agents that are widely used in clinical transplantation. We investigated whether the in vivo induction of T cell unresponsiveness contributes to the immunosuppressive properties of the anti-mouse-CD3 mAb 145-2C11.
After a single in vivo administration of 145-2C11 residual T cells were restimulated in vivo and in vitro to assess cytokine production. Mice were also transplanted with allogeneic skin 9 days after 145-2C11 administration to investigate whether the immunosuppressive properties of the antibody persist after the reexpression of the T cell receptor.
Pretreatment with anti-CD3 mAbs caused a profound deficit in both interleukin- (IL) 2 and interferon- (IFN) y secretion upon restimulation in vivo, whereas IL-4 was only partially inhibited and IL-10 production was significantly increased. Purified T cells obtained from mice injected with anti-CD3 mAb also displayed deficient IL-2 and IFN-gamma production together with persisting IL-4 and IL-10 secretion. 145-2C11 had immunosuppressive properties that per sisted after the reexpression of the T cell receptor because mice transplanted with allogeneic skin 9 days after a single anti-CD3 mAb injection still had significantly prolonged graft survival (14.1+/-0.6 days vs. 10.7+/-0.4 days in controls, P<0.02). Blocking IL-4 and IL-10 by neutralizing mAbs further prolonged skin graft survival in mice injected with 145-2C11 (18.3+/-0.7 vs. 14.8+/-0.6 days, P<0.02).
The in vivo administration of the 145-2C11 anti-CD3 mAb results in the selective inhibition of Thl-type cytokine secretion upon restimulation, which correlates with a state of immunosuppression. The persistent production of Th2-type cytokines does not contribute to the anti-CD3 mAb-mediated prolonged survival of skin allografts in our experimental model.
激活型抗CD3单克隆抗体(mAb),如OKT3,是强效免疫抑制剂,广泛应用于临床移植。我们研究了体内诱导T细胞无反应性是否有助于抗小鼠CD3 mAb 145-2C11的免疫抑制特性。
单次体内给予145-2C11后,对残留T细胞进行体内和体外再刺激以评估细胞因子产生。在给予145-2C11 9天后,小鼠也接受同种异体皮肤移植,以研究在T细胞受体重新表达后抗体的免疫抑制特性是否持续存在。
抗CD3 mAb预处理导致体内再刺激时白细胞介素-(IL)2和干扰素-(IFN)γ分泌均显著减少,而IL-4仅部分受抑制,IL-10产生显著增加。从小鼠体内注射抗CD3 mAb获得的纯化T细胞也表现出IL-2和IFN-γ产生不足,同时IL-4和IL-10持续分泌。145-2C11具有免疫抑制特性,在T细胞受体重新表达后仍然存在,因为在单次注射抗CD3 mAb 9天后接受同种异体皮肤移植的小鼠,其移植物存活时间仍显著延长(14.1±0.6天对对照组的10.7±0.4天,P<0.02)。用中和mAb阻断IL-4和IL-10可进一步延长注射145-2C11小鼠的皮肤移植物存活时间(18.3±0.7天对14.8±0.6天,P<0.02)。
体内给予145-2C11抗CD3 mAb导致再刺激时Th1型细胞因子分泌被选择性抑制,这与免疫抑制状态相关。在我们的实验模型中,Th2型细胞因子的持续产生对抗CD3 mAb介导的皮肤同种异体移植物存活时间延长没有作用。